[Effects of lipid-modulation and antiplatelet treatment on the endothelial lipase expression].
OBJECTIVE
To investigate the effects of lipid-modulation and antiplatelet treatment on the expression of endothelial lipase (EL) of patients with coronary artery disease (CAD), and investigate the role of EL in the development of CAD.


METHODS
One hundred and fifty-seven cases were divided into three groups according to clinical manifestations and the results of coronary artery angiography: control group (n=41) with more than one risk factors of CAD and the vessel lesions was <30%; stable angina pectoris (SAP) group (n=55); acute coronary syndrome (ACS) group (n=61). The EL positive cell rate was measured 2 weeks after cessation of lipid-modulation and aspirin treatment, and 6 months after treatment with simvastatin and/or aspirin. The drug was ceased for the complications or not tolerance for the treatment.


RESULTS
Except the patients in control group with aspirin treatment, the EL positive cell rate was significantly decreased among other groups [control group with simvastatin: (3.93±0.87)% vs. (5.28±1.05)%, SAP group: (8.16±2.11)% vs. (15.12±2.53)%, ACS group: (13.93±3.22)% vs. (38.44±4.36)%; SAP group with aspirin: (10.57±4.07)% vs. (14.66±2.29)%, ACS group: (18.28±5.14)% vs. (40.27±3.96)%; control group with aspirin and simvastatin: (3.13±0.87)% vs. (5.33±1.25)%, SAP group: (5.68±2.20)% vs. (14.89±2.15)%, ACS group: (7.81±3.96)% vs. (39.27±5.17)%, P<0.05 or P<0.01].


CONCLUSIONS
The treatment with lipid-modulation and/or antiplatelet drug may significantly decrease the expression of EL, implying that EL participates in the progression of CAD.
Department of Cardiology, the Third Military Medical University, Chongqing 400042, China. yuqfang@163.com
Yu-qiang
YQ
Fang
Duo-fen
DF
He
Cheng-ming
CM
Yang
Xu-kai
XK
Wang
Chun-yu
CY
Zeng
Hong-yong
HY
Wang
Chun-jiang
CJ
Fu
Wei-bin
WB
Shi
Ye
Y
Zhang
D000328:Adult; D000368:Aged; D001792:Blood Platelets; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008049:Lipase / Q000378:metabolism*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D008055:Lipids; D019821:Simvastatin; C410382:LIPG protein, human; D008049:Lipase